**Move beyond the threshold**

As an extended half-life recombinant FVIII, Esperoct® offers a simple way to reach higher trough FVIII activity levels compared to standard half-life treatments.*1,4-9

*40°C storage for up to 3 months before reconstitution**

**Esperoct® is licensed for the treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia A (congenital factor VIII deficiency). The safety and efficacy of Esperoct in previously untreated patients has not yet been established.**

In adults and adolescents (12 years and over) with severe haemophilia A, Esperoct® demonstrated:

- A simple, fixed dose:11,14
  - 50 IU/kg every 4 days

Higher trough FVIII activity levels vs. SHL treatments:1,4-9

Mean trough FVIII activity levels of 3%

Low ABR:1,14

Median total ABR*: 1.18

This Novo Nordisk advertisement is intended for UK Healthcare Professionals.

---

**Prescribing Information**

**Esperoct**® Powder and solvent for solution for injection Turoctocog alfa pegol Esperoct® 500 IU Esperoct® 1000 IU Esperoct® 1500 IU Esperoct® 2000 IU Esperoct® 3000 IU Indication: Treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia A (congenital factor VIII deficiency). 

**Serology and administration:** The dose, dosing interval and duration of the substitution therapy depend on the severity of the factor VIII deficiency, on the location and extent of the bleeding, on the targeted factor VIII activity level and the patient's clinical condition. On demand treatment and treatment of bleeding episodes: Required dose IU = body weight (kg) x desired factor VIII rise (%)/ IU 4 IU (x 0.5 kg per IU). Mild hemarthrosis: early haemarthrosis, mild muscle bleeding or mild oral bleeding. Factor VIII level required (U/dL or % of normal): 20-40. Frequency of doses: 12-24, until the bleeding is resolved. Moderate haemarthrosis: More extensive haemarthrosis, muscle bleeding, haematoma. Factor VIII level required (U/dL or % of normal): 50-80. Frequency of doses: 12-24, until the bleeding is resolved. Severe or life-threatening haemarthroses: Factor VIII level required (U/dL or % of normal): 65-100. Frequency of doses: 6-24, until the treated is restored. Postoperative management: Minor surgery: Indicating an estimated postoperative need for 20-40% of normal factor VIII level. Post-operative: Frequency of doses (hours): within 1 hour before surgery; repeat after 4 hours if necessary. Duration of therapy: single dose or repeat injection every 24 hours for at least 1 day until healing is achieved. Major surgery: Indicating an estimated need for 80-120% of normal factor VIII level. Preoperative: Frequency of doses (hours): Within 1 hour before surgery to achieve factor VIII activity within the target range. Repeat every 8-24 hours to maintain factor VIII activity within the target range. Repeat injection every 8-24 hours as necessary. Adjustment of doses and administration intervals may be considered based on achieved factor VIII levels and individual bleeding tendency. Paediatric population: The dose in adolescents (12 years and above) is the same as for adults. In children below 12 years long-term safety has not been established. Method of administration: Intravenous injection (over approximately 2 minutes) after reconstruction of the powder with NaCl, supplied solvent (sodium chloride 9 mg/ml, 0.9% solution) for injection. Contraindications: Hypersensitivity to the active substance or to any of the excipients, or to hamster protein. Special warnings and precautions for use: Name and the batch number of the administered product should be clearly recorded to improve traceability. Hypersensitivity. Allergic-type hypersensitivity reactions are possible due to traces of hamster proteins, which in some patients may cause allergic reactions. If symptoms of hypersensitivity occur, patients should be advised to immediately discontinue the use of the medicinal product and contact their physician. Patients should be informed of the early signs of hypersensitivity reactions including hives, generalised urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis. In case of shock, standard medical treatment for shock should be administered. 

**Infections:** The formation of neutralising antibodies (inhibitors) to factor VIII is a known complication in the management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the factor VIII procoagulant activity, which are quantified in Bethesda Units (BU) per ml of plasma using the modified assay. The risk of developing inhibitors is correlated to the severity of the disease as well as the exposure to factor VIII, this risk being highest within the first 50 exposure days but continues throughout life although the risk is uncommon. The clinical relevance of inhibitor development will depend on the titre of the inhibitor, with low titre posing less of a risk of insufficient clinical response than high titre inhibitors. Patients treated with coagulation factor VIII products should be monitored for the development of inhibitors by appropriate clinical observations and laboratory tests. If the expressed factor VIII activity plasma levels are not attained, or if bleeding is not controlled with an appropriate dose, testing for factor VIII inhibitor presence should be performed. In patients with high levels of inhibitor, factor VIII therapy may not be effective and other therapeutic options should be considered. Cardiovascular events: In patients with existing cardiovascular risk factors, substitution therapy with factor VIII may increase the cardiovascular risk. Carbohydrate-related complications, if a central venous access device (CVA) is required, the risk of CVA-related complications including local infections, bacteremia and catheter site thrombosis should be considered. Paediatric population: Listed warnings and precautions apply both to adults and adolescents (12-18 years). Exipient-restricted considerations: Product contains: 30.5 mg sodium per reconstituted vial, equivalent to 1.5% of the WtH recommend maximum daily intake of 2.0 g sodium for an adult. Fertility, pregnancy and lactation: Animal reproduction studies have not been conducted with factor VIII. Based on the rare occurrence of haemophilia A in women, experience regarding the use of factor VIII during pregnancy and breast-feeding is not available. Therefore, factor VIII should be used during pregnancy and lactation only if clearly indicated. Undesirable effects: Adverse events in clinical trials which could be considered serious include: (±10%) Rash, pruritus, urticaria, injection site reactions (>1%,≤10%) Factor VIII inhibition, hypersensitivity. The Summary of Product Characteristics should be consulted in relation to other adverse reactions, MA numbers and Basic NHS Price: Esperoct® 500 IU EU/1/191374/001 E425 Esperoct® 1000 IU EU/1/191374/002 E850 Esperoct® 1500 IU EU/1/191374/003 E1,275 Esperoct® 2000 IU EU/1/191374/004 E1,700 Esperoct® 3000 IU EU/1/191374/005 E2,350 Legal category: PCN. For full prescribing information please refer to the SmPC which can be obtained from the Marketing Authorisation Holder: Novo Nordisk Limited, 3C City Place, Beehive Ring Road, Gatwick, West Sussex, RH6 0PA. Marketing Authorisation Holder: Novo Nordisk A/S, Novo Allé, DK-2880 Bagsvaerd, Denmark. Date last revised: September 2020

---

**Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0845 6000505). Calls may be monitored for training purposes.**

**Esperoct® is a trademark owned by Novo Nordisk Health Care AG, Switzerland. ABR, annualised bleed rate. BHL, extended half-life FVIII; factor VIII; FVIII: reconbinant factor VIII; SHL, standard half-life.**

*Previously treated patients, 12 years and above. **Prophylaxis: The recommended dose is 50 IU of Esperoct per kg body weight every 4 days. Adjustments of doses and administration intervals may be considered based on achieved factor VIII levels and individual bleeding tendency. *Racial ABR includes all bleedings spontaneous, traumatic and joint bleedings.

**References:**

Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy

Sorcha Forde,1 Jamie D. Matthews,1 Leila Jahangiri,2,3 Liam C. Lee,1 Nina Prokoph,1 Tim L.M. Malcolm,1 Olivier T. Giger,1 Natalie Bell,3 Helen Blair,3 Aengus O’Marcaigh,4 Owen Smith,4 Lukas Kenner,5,6,7 Simon Bomken,5,8,9 Gladstone A. A. Burke10,* and Suzanne D. Turner1,11,*
1Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, 2Department of Life Sciences, Birmingham City University, Birmingham, 3Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK, 4Children’s Health Ireland at Crumlin, Dublin, Ireland, 5Department of Pathology, Medical University of Vienna, Vienna, 6Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, 7Christian Doppler Laboratory for Applied Metabolomics, Vienna, Austria, 8The Great North Children's Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, 9Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, 10Department of Paediatric Oncology and Haematology, Addenbrooke’s Hospital, Cambridge, UK, and 11Central European Institute of Technology, Masaryk University, Brno, Czech Republic

Received 15 June 2020; accepted for publication 26 July 2020
Correspondence: Suzanne D. Turner, Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Lab Block Level 3, BOX 231, Addenbrookes Hospital, Cambridge CB20QQ,

Summary
Burkitt lymphoma (BL) accounts for almost two-thirds of all B-cell non-Hodgkin lymphoma (B-NHL) in children and adolescents and is characterised by a MYC translocation and rapid cell turnover. Intensive chemotherapeutic regimens have been developed in recent decades, including the lymphomes malins B (LMB) protocol, which have resulted in a survival rate in excess of 90%. Recent clinical trials have focused on immunochemotherapy, with the addition of rituximab to chemotherapeutic backbones, showing encouraging results. Despite these advances, relapse and refractory disease occurs in up to 10% of patients and salvage options for these carry a dismal prognosis. Efforts to better understand the molecular and functional characteristics driving relapse and refractory disease may help improve this prognosis. This study has established a paediatric BL patient-derived xenograft (PDX) resource which captures and maintains tumour heterogeneity, may be used to better characterise tumours and identify cell populations responsible for therapy resistance.

Keywords: Burkitt lymphoma, patient derived xenograft, relapse, B-cell lymphoma, murine cancer models.

© 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

doi: 10.1111/bjh.17043
B-cell non-Hodgkin lymphoma (B-NHL) represents the most common subtype of NHL in childhood and adolescence, accounting for up to 60% of all newly diagnosed lymphomas.1,2 Burkitt lymphoma (BL) alone accounts for almost two-thirds of B-NHL in children and adolescents and is most prominent in the 0–14 age group.3 The defining characteristic of BL is a translocation of the MYC oncogene on chromosome 8 with the immunoglobulin genes on chromosomes 14, 22 or 2 and it presents in advanced form (stage III/IV) in 70% of patients.4,5 In the modern era, all aggressive mature paediatric B-NHL patients receive the same treatment regimens and outcomes have improved dramatically in recent decades, with trials showing survival of approximately 90%.6–8 The clinical focus has been on establishing risk-stratification to reduce the acute and long-term toxicities associated with therapy for those patients with a favourable prognosis. Recent clinical trials in paediatric B-NHL involve the combination of rituximab, an anti CD20 antibody, with a chemotherapeutic backbone, based on the rationale that the CD20 antigen is present in over 98% of cases of paediatric mature B-NHL.9 The addition of rituximab to a modified lymphomas malins B (LMB) chemotherapy regimen has recently been evaluated in the Inter-B-NHL Ritux study with results showing prolonged event-free survival and overall survival among children and adolescents with high-grade, high-risk, mature B-NHL.10 Despite these developments, prognosis in refractory and relapse cases remains dismal, with few options to successfully salvage patients and the two-year overall survival rate with chemoimmunotherapy reported as 15–33%.11,12 The cellular population(s) responsible for propagating refractory/relapsed disease have not yet been identified, largely due to the lack of suitable model systems.13

Patient-derived xenograft (PDX) models have evolved as a powerful preclinical tool capable of bridging the gap between established cell lines and primary tumour samples. PDXs better maintain the heterogeneity of patient tumours and hence allow for a more clinically relevant examination of tumour evolution, response to therapy and development of chemo-resistance. Despite a relatively homogeneous histological appearance, studies have demonstrated both inter- (across patients) and intra-(within tumours) heterogeneity in BL.14,15 Love et al.16 reported considerable heterogeneity in the number of mutated genes across samples: out of a total of 70 mutated genes, the range of mutations in the sample cohort was 2 to 16. Model systems such as PDXs which capture the genetic and functional heterogeneity of primary paediatric BL will be necessary to identify targeted therapies for individual patients, as well as to decipher the clonal dynamics that lead to resistant disease in 5–10% of patients.5 PDX models of B-cell lymphoma exist, although those published have been developed from adult tumours and consist mainly of the Diffuse Large B-cell Lymphoma (DLBCL) subtype, the most common B-cell lymphoma in the adult population, and their applicability to paediatric B-NHL is limited.17 This paper documents, to our knowledge, the establishment of the largest PDX resource for paediatric BL, providing a valuable tool to characterise tumours and better understand the functional and molecular characteristics of this tumour type.

Materials and methods

Primary patient samples

Paediatric B-NHL primary patient samples were obtained from redundant tissue taken at the time of the diagnostic biopsy, following informed consent on enrolment of patients to the Inter B-NHL Ritux clinical trial or following local ethical approval (Research Ethics Committee Reference: 07/q0104/16). One patient sample was obtained with informed consent from the Newcastle Haematology Biobank (Research Ethics Committee Reference: 07/H0906/109+5). One patient biopsy (to generate PDX6) was obtained at relapse from a drained peritoneal effusion of a patient refractory to ICE (ifosfamide, carboplatin, etoposide) therapy.

Patient sample processing

Mononuclear cells (MNCs) were isolated from pleural effusion, peripheral blood or bone marrow by gradient centrifugation over Lymphoprep™ (STEMCELL Technologies, Cambridge, UK). Tumour samples from solid biopsies underwent mechanical disaggregation by passing cells through a 70 µmol/l nylon cell strainer (BD Falcon, Erembodegem, Belgium) using the plunger of a 5 ml syringe (BD Plastipak, BD Falcon), applying light to medium mechanical force. Isolated MNCs were washed once with phosphate-buffered saline (PBS, ThermoFisher, Waltham, MA, USA) before injection into mice or further analysis.

Mice

JAX™ NSG Mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) were obtained from Charles River, Margate, UK and housed in
individually ventilated cages (IVCs) under sterile pathogen-free (spf) conditions at the University of Cambridge under project licence numbers 80/2630 (2014–2017) and P4DEFF63 (2018–2020). Additional animals in Newcastle were housed and used under project licence 60/4552 (2013–2018).

Tumour growth in NSG mice

Isolated MNCs (5 \times 10^6) were suspended in 200 µl of PBS and mixed with 200 µl of matrigel (Corning, Flintshire, UK) before 300 µl of suspension was injected subcutaneously (SC) or intraperitoneally (IP) into NSG mice. Once tumours reached the maximum regulatory allowed size of 1.2 cm (1.5 cm in 10% of cases) in any one direction, animals were culled and the tumour removed and disaggregated by passing cells through a 70 µm cell strainer (BD Falcon). For serial passage, cells (1 \times 10^6) were resuspended in matrigel as described and re-injected.

Fluorescence in situ hybridization

Fluorescent in situ hybridization (FISH) was carried out to determine the presence of the MYC translocation. Single-cell suspensions were collected by centrifugation at 200 g for 5 min and resuspended in Carboxyl’s Fixative (3:1 methanol: glacial acetic acid). FISH was performed using a Vysis LSI IGH/MYC/CEP 8 Tri-Color Dual Fusion Probe Kit (Abbott Diagnostics, Maidenhead, UK). Results were reported as the percentage of cells positive for IGH—MYC rearrangement as well as the signal pattern.

Tumour histology

Following extraction of tumours, either the whole tumour or a representative biopsy was immediately placed in 10% neutral-buffered formalin (Sigma-Aldrich, Gillingham, UK). After 24 h the tumour was removed and placed in 70% ethanol/PBS. Tumours were embedded in paraffin before sections were cut and stained with haematoxylin and eosin using standard procedures. Sections were analysed by a histopathologist at the Department of Pathology, University of Cambridge and images captured at 20x magnification.

Flow cytometry

Cells were washed with PBS and collected by centrifugation at 250 g for 5 min before resuspension in flow cytometry buffer [PBS, 0.05% Bovine Serum Albumin (ThermoFisher, Wattham, MA, USA)] at a concentration of 1 \times 10^6 cells/ml. Cell suspension (100 µl) was added to each well of a 96-well plate and stained with the following: murine phycoerythrin, fluorescent isothiocyanate, allophycocyanin or cyanine 7 (Cy7)—conjugated antibodies: CD9, CD10, CD19, CD20, CD21, CD24, CD27, CD34, CD38, CD40, CD44, CD45, CD49d, CD49f, CD59, CD90, CD117, CD133, CD184, ABCG2 (BD Biosciences, Erembodegem, Belgium). After staining (40 min at 4°C, 1:100), cells were washed in PBS and resuspended in 2 ml of flow cytometry buffer before immediate analysis on a BD Accuri C6 or a LSR Fortessa Flow Cytometer. At least 10 000 events were recorded and data analysed with FlowJo v9.1 (BD, Erembodegem, Belgium). The lymphocyte population was selected and expression levels determined based on gates set using unstained control.

Whole genome sequencing

DNA was extracted with a DNeasy Blood & Tissue Kit (Qiagen, Manchester, UK) and whole genome sequencing (WGS) was performed on the Illumina Novaseq 6000 (Cambridge, UK). Sequencing reads in FASTQ format were quality-checked with FastQC (version 0.11.9; Babraham Bioinformatics, Cambridge, UK, https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and mapped to the hg38 human genome assembly using BWA (0.7.17-4, Heng Li, Boston, MA, USA, https://github.com/lh3/bwa) with the ‘-M’ compatibility option. BAM files were coordinate-sorted with Samtools (1.0–10–3, Genome Research Limited, Saffron Walden, UK, http://www.htslib.org/). Duplicate marking and base quality score recalibration was performed with the GATK suite (4.1.4–0, Broad Institute, Cambridge, MA, USA, https://gatk.broadinstitute.org/). Single nucleotide variants (SNVs) and small insertions and deletions (indels) were called and filtered using GATK Mutect2 and FilterMutectCalls with recommended parameters, and annotated with SnvEff (4.3, Pablo Cingolani, https://pcingola.github.io/SnpEff/). To compile a list of genes with possible involvement in BL pathophysiology, we took the union of: COSMIC (Wellcome Sanger Institute, Hinxton, UK, https://cancer.sanger.ac.uk/cosmic) ‘Genes with mutations’ for BL histology, genes mutated in the validation cohort of Grande et al. 18 and recurrently mutated genes from the Love et al. 16 cohort, yielding 4 272 genes. To enrich for functional variants, intergenic, intronic, and synonymous SNVs were excluded. To avoid including potential germline variants, variant allele frequencies (VAFs) in the range (0, 0.97) were included. Data visualisation and statistical analysis was performed in R: The R Project for Statistical Computing (https://www.r-project.org/).

RT-qPCR quantification of gene expression

All kits were used according to the manufacturer’s instructions. To compare gene expression levels, total RNA was isolated with the RNAtasy Plus Mini Kit (Qiagen) before RNA (1 µg) was reverse transcribed using the ProtoScript II First Strand cDNA Synthesis Kit (NEB, Ipswich, MA, USA). RT reactions were diluted (1:10) and 10 ng equivalent (to input RNA amount) was used as the template DNA for quantitative polymerase chain reaction (qPCR) using Power SYBR Green PCR Master Mix (ThermoFisher) with standard reaction conditions on the QuantStudioTM 6 Flex Real-Time
Table I. Details of biopsy site, diagnosis, disease stage and engraftment status for each patient sample and the resulting patient-derived xenograft (PDX).

<table>
<thead>
<tr>
<th>Sample number</th>
<th>Patient</th>
<th>Biopsy site</th>
<th>Diagnosis</th>
<th>Stage</th>
<th>Engraftment success</th>
<th>PDX formed</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>Needle biopsy of abdominal mass</td>
<td>Burkitt lymphoma</td>
<td>III</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>1</td>
<td>Bone marrow</td>
<td>Burkitt lymphoma</td>
<td>III</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>Pleural effusion</td>
<td>Burkitt lymphoma</td>
<td>III</td>
<td>Yes</td>
<td>PDX1</td>
</tr>
<tr>
<td>4</td>
<td>3</td>
<td>Peripheral blood</td>
<td>Burkitt lymphoma/leukaemia with CNS involvement</td>
<td>IV</td>
<td>Yes</td>
<td>PDX2</td>
</tr>
<tr>
<td>5</td>
<td>3</td>
<td>Bone marrow</td>
<td>Burkitt lymphoma/leukaemia with CNS involvement</td>
<td>IV</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>4</td>
<td>Bone marrow</td>
<td>Burkitt lymphoma</td>
<td>IV</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>5</td>
<td>Bone marrow</td>
<td>Burkitt lymphoma</td>
<td>IV</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>6</td>
<td>Bone marrow</td>
<td>Burkitt lymphoma</td>
<td>III</td>
<td>Yes</td>
<td>PDX3</td>
</tr>
<tr>
<td>9</td>
<td>7</td>
<td>Pleural effusion</td>
<td>Burkitt lymphoma</td>
<td>III</td>
<td>Yes</td>
<td>PDX4</td>
</tr>
<tr>
<td>10</td>
<td>8</td>
<td>Pleural effusion</td>
<td>Burkitt lymphoma</td>
<td>IV</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>9</td>
<td>Bone marrow</td>
<td>Burkitt lymphoma</td>
<td>IV</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>9</td>
<td>Bone marrow</td>
<td>Burkitt lymphoma</td>
<td>IV</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>10</td>
<td>Peritoneal effusion</td>
<td>Burkitt lymphoma</td>
<td>Relapse</td>
<td>Yes</td>
<td>PDX6</td>
</tr>
</tbody>
</table>

All samples were received following procedure to obtain diagnostic biopsies prior to treatment except for sample 14 from patient 10 that was taken when the patient had relapsed and was refractory to therapy with ICE (ifosfamide, carboplatin, etoposide). CNS, central nervous system.

PCR System (ThermoFisher). PCR was carried out using primers specific to the following genes: MYC FWD 5’-GGCTCCTGGCAAAAGGTCA-3’, MYC R 5’-CTGGTAGCTGTGCTGATGT-3’; BCL2 FWD 5’-GGTGAGTGCTGTGCTGATGTG-3’, BCL2 R 5’-CGCTGACGTGTTCTCCTCG-3’; BCL6 FWD 5’-ACACATACTGTCAATTGTC-3’, BCL6 R 5’-AGTGTCCACAACATGCTCCAT-3’; GNA13 FWD 5’-CCCAGAAATGTTGGAACAA-3’, GNA13 R 5’-ACCAGTTTGAATTTCTCGAGC-3’; ID3 FWD 5’-GAGGAGCATACCTGGTTAGGCATCTG-3’, ID3 R 5’-TCCTTTTGTCTGGTGGATGAC-3’; TCF3 FWD 5’-CCGACTCTCAATGGTGGCTA-3’, TCF3 R 5’-CGGCTAGCGTTCTCTTTATCG-3’; PIM1 FWD 5’-GAGAGAGCGATTTCCGAC-3’, PIM1 R 5’-CATGTCAGGAGCCAAATGACGCTG-3’; ARID1A FWD 5’-CCAGAGCGAACTCTCAGGAC-3’, ARID1A R 5’-GTGAGGAAAGGACGATTCC-3’; CDK4 FWD 5’-ATGGCTACCTTCCTCTGATATGAC-3’, CDK4 R 5’-CATTGGGGAATCTCAGACTCTCTCTC-3’; CDC7 FWD 5’-AGTTGCTAAACGTGGCTG-3’, CDC7 R 5’-CAGGATGGAAATACCAGGGGACCTG-3’; GAPDH FWD 5’-GGAGGAGATCCCTCTCAAAAT-3’, GAPDH R 5’-GGCGTGTACATTTCTCTAGG-3’; PTEN FWD 5’-TTTGGAGGACATTAAACCCACAC-3’, PTEN R 5’-ATTACACAGTTGGTCCCTTTTC-3’, PAX5 FWD 5’-ACTTGTCTACATGGTTGCACTG-3’, PAX5 R 5’-TAATCAATCCGAGGGTTATTA-3’, MTO1 FWD 5’-TCCGAGATGATGTCGAGG-3’, MTO1 R 5’-CACTTTTACTTCTGAGGAGG-3’, SMARCA4 FWD 5’-GACCACATCCACCAAGGTTAC-3’, SMARCA4 R 5’-CTGGCCTGGAAGACATCTG-3’.

Data were analysed using the double delta Ct (ΔΔCt) method conducted with normalization to GAPDH (ΔCt) before relative expression level comparison to the control sample (ΔΔCt). All qPCR reactions were performed in technical triplicates.

Results

Establishment of PDX models from paediatric Burkitt lymphoma biopsy material

Samples from paediatric patients diagnosed with BL were taken from various sites including tumour biopsy (n = 1),

Fig 1. Tumour cell characteristics are maintained following engraftment in NSG mice. (A) Mononuclear cells (MNCs) were isolated from a patient pleural effusion sample and resuspended in phosphate-buffered saline (PBS) before injection via the subcutaneous (left) or intraperitoneal route (right). (B) The lymphocyte population of patient sample 3 pleural effusion was analysed for expression of surface antigen before and after engraftment in a mouse [patient-derived xenograft (PDX) 1]. (D) Overview of surface antigen expression before and after engraftment. Heatmap represents percentage surface antigen expression as determined by flow cytometry. (E) The tumourigenic cell population in a peripheral blood sample (patient sample 4, PDX2) and a bone marrow sample (patient sample 9, PDX3) were identified based on expression of CD20. (F) MNCs from initial peripheral blood biopsy sample of patient sample 4 and after passage 1 (PDX2) were analysed for expression of surface antigens CD117 and ABCG2. [Colour figure can be viewed at wileyonlinelibrary.com]
PDX of Burkitt Lymphoma Recapitulate Disease Characteristics

(A) Subcutaneous Intraperitoneal

(B) Pleural effusion Isolated MNCs

(C) Pre-enuirement

(D) Passage 1

(E) PDX2

(F) Patient sample Passage 1

© 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd
peritoneal fluid ($n=1$), pleural effusion ($n=3$), bone marrow ($n=6$) and peripheral blood ($n=3$) (Table I). In total, 14 samples were obtained from 10 patients with six samples resulting in successful engraftment; an engraftment rate of 43%. The primary method of engraftment was subcutaneous (SC) injection of mononuclear cells (MNCs) with matrigel, although cells were also injected in separate mice intraperitoneally (IP) and intravenously (IV) when sufficient numbers were available. Of note, IV injection was attempted for all tumour samples from peripheral blood and bone marrow but no engraftment of Burkitt cells in the peripheral blood of mice was detected. In all cases where SC injection resulted in tumour engraftment, IP injection of cells from the same sample also successfully engrafted (Fig 1A). Pleural effusion samples engrafted most consistently with 3/3 forming a PDX while 0/1 solid tumour, 1/1 peritoneal fluid, 1/3 peripheral blood and 1/6 bone marrow samples were successfully engrafted. The only sample of peritoneal fluid, also the only tumour from a relapse patient, was engrafted SC only and formed a tumour.

Given that all but one biopsy sample were obtained in liquid form from sites with potentially mixed cell populations, non-tumour cells were initially depleted from all peripheral blood, pleural effusion and bone marrow samples by gradient centrifugation. This resulted in an enrichment of lymphocytes including the B-cell tumour population. For example, lymphocytes increased from 5 to 55% of the cell population of the pleural effusion (Fig 1B) after MNC isolation of patient sample 3, the first sample to form a PDX. This enriched lymphocyte population was $CD10^{+}CD20^{+}$, a
Importantly, the surface phenotype of the PDX1 cell population after passage 1 was indistinguishable from that of the lymphocyte population of the pleural effusion biopsy sample from which it was derived (patient sample 3; Fig 1C, D). PDX5, also derived from a pleural effusion sample, showed similar maintenance of the lymphocyte cell surface phenotype between biopsy and passage 1 (Fig 1D). PDX2 and PDX3 were derived from peripheral blood and bone marrow patient samples, respectively, with a mixed population of healthy and tumourigenic blood cells within the biopsy samples (Fig 1E). Once the PDX had been established, that is, tumours grew in the mice on first passage, 96% of lymphocytes in PDX2 and 95% in PDX3 were CD20+, compared to 84% and 42% of the total lymphocyte population, respectively, in the original patient biopsies, suggesting that tumour cells are selected in vivo (Fig 1D,E). Conversely, the small population of CD117+ cells present in the starting material for PDX2 was lost in the established graft, although these cells were CD20+ suggesting they were not tumour cells (Fig 1F). However, a minor population of CD20+ABCG2+ cells was present in the initial biopsy and in the established graft, suggesting that even minor cell populations within the patient biopsy sample were maintained in the PDX on engraftment (Fig 1F). PDX4 did not have spare biopsy material available for analysis.

To investigate the maintenance of genetic intratumour heterogeneity in the PDX model employed in this study, WGS was performed on the PDX developed from a relapse BL peritoneal fluid sample that had sufficient material both at biopsy and after passage 1 (PDX6). Importantly, no new variants in BL-related genes emerged or were lost following expansion of the xenograft in vivo (Fig 2; Figure S1). Furthermore, linear regression of VAFs before and after passage yielded an adjusted R² statistic of 0.95, indicating a good fit (slope: 0.98, intercept: 0.03, P < 2.2 × 10⁻¹⁶).

PDX models maintain their phenotypic, molecular and histopathological features through passage

To validate that PDX models are a robust and reliable resource that recapitulate the features of paediatric BL through propagation in mice, tumours were monitored at each passage. Histopathological analysis of each tumour after passages 1 (P1) and 5 (P5) was performed showing maintenance of high-grade lymphoma histology (Fig 3A). The characteristic MYC translocation of BL was identified at diagnosis for each patient and maintenance of the translocation signal in all PDX cells was monitored through passage using FISH. At P5, for all of the PDX (PDX1–5), the specific MYC translocation was maintained in almost 100% of tumour cells (Fig 3B). To determine if serial passage impacts the expression profile of tumours, expression profiling of genes associated with BL was conducted at P1 and P5. The coefficient of determination between P1 and P5 for each PDX was greater than 0.94, highlighting consistent expression levels of this limited selection of genes at both passages (Fig 3C; Figure S2). Comparison with the original diagnostic material was not possible, as there was insufficient material available.

Cell surface expression profiling between passages 1 and 5 also highlighted that all tumours faithfully maintained their surface expression profile over passage. All five PDXs showed strong expression of surface proteins characteristic of BL, such as CD20+, while minor populations of tumour cells were also maintained within each PDX, for example, ABCG2+ cells (Fig 3D). This highlights the significant intratumour heterogeneity within these PDX models which was also maintained through multiple passage (Fig 3D). The maintenance of precise surface expression profiles within each PDX, over five passages, highlights the existence of an intricate population equilibrium within the individual tumours. Importantly, subpopulations that were maintained through passage, at varying levels in the five PDXs, included populations not commonly reported in BL such as CD9+, CD90+, CD44+ and CD49D+ cells (Fig 3D).

PDXs can be used to mimic response to therapy in vivo

The mean number of days for the injected primary cells to first produce palpable tumours when engrafted SC was 33 (range 28–48 days) with PDX3 from a bone marrow sample having the longest engraftment time (Fig 4A). Once established, passage 2 of each PDX led to the development of palpable tumours more quickly (Fig 4A) and the total time from injection to produce tumours of maximum allowed size, according to UK guidelines, was largely consistent for each PDX across passages, from P2 onwards (Fig 4B). The ability of these PDX models to give rise to large, palpable...
PDX of Burkitt Lymphoma Recapitulate Disease Characteristics

(A) Days

Passage 1  Passage 2

(B) Days

Passage 2  Passage 3  Passage 4  Passage 5

(C) Change in weight (%)

Chemotherapy  Vehicle control

(D) Tumour volume (mm³)

PDX1

No chemotherapy  Chemotherapy  Chemotherapy (increased concentration)

PDX2

PDX3

PDX4

PDX5

Time (Days)
tumours within a relatively short timeframe provides an excellent resource to conduct in vivo experiments and investigate patient-specific tumour characteristics, such as heterogeneity and response to therapy. Multi-agent chemotherapy (doxorubicin, methotrexate and vincristine) was administered every 72 h, once tumours reached a volume of 400 mm³. Chemotherapy was stopped after a maximum of six doses when tumours shrank to 50 mm³. Chemotherapy led to a discrete but significant weight loss for all 5 PDX models compared to vehicle-only controls (Fig 4C). In the case of PDX 1, 2, 3 and 5, tumours responded to lower-dose chemotherapy based on decreased tumour volumes (Fig 4D), whereas PDX4 only showed a significant treatment response upon administration of an increased concentration of multi-agent chemotherapy.

Discussion

Survival rates in paediatric BL approach 90% but salvage options in relapse and refractory disease remain very limited.5 It is necessary for us to develop a greater understanding of the different populations within tumours to reduce the use of toxic chemotherapy and to develop targeted therapies for difficult-to-treat chemoresistant relapse and refractory cases. In evidence, studies have shown that personalised therapeutic approaches designed according to PDX treatment responses result in improved clinical outcomes.19 For adult B-NHL, due to the genetic heterogeneity of tumours, several different pathways leading to drug resistance have been identified and this is also likely the case for paediatric BL. Chemoresistance in paediatric BL may, therefore, require the development of personalised approaches to address patient-to-patient genetic heterogeneity. In this study we have successfully established PDX models of paediatric BL and demonstrated their ability to faithfully maintain molecular and phenotypic characteristics through multiple passages. This ensures the model possesses a high level of clinical relevance and can be used for identifying populations with chemoresistance potential as well as to investigate the potential efficacy of targeted therapies.

Patients in this study presented with both BL and leukaemia and PDXs were mainly established from liquid biopsies from peripheral blood, bone marrow, pleural effusion and peritoneal fluid. The only solid biopsy sample included did not lead to PDX establishment. An engraftment rate of 43% was observed when considering all specimens received and each of the engrafted PDX were successfully propagated by long-term serial passage. This rate is comparable to that in many other similar studies with one review of existing data highlighting that engraftment rates typically vary between 23% and 75% depending on the tumour type.20 A study of adult B-NHL, including mainly mantle cell lymphoma (MCL) and DLBCL, with one BL sample had a 67% success rate for serial passage21 and a further study in DLBCL reported a 32% success rate for serial passage.17 Pleural effusion samples had the highest engraftment rate in this study, although one PDX developed from peripheral blood and another from bone marrow via both the IP and SC routes. In contrast, tumour growth was not observed, independent of the site of origin, when engrafted IV. Given these potential limitations, a key consideration when utilising PDXs as a model for cancer is to determine how well they represent the original patient disease. In this study, PDX models established from pleural effusions showed a strong phenotypic correlation with the biopsy material, likely because there are fewer non-tumourigenic immune cells in the pleural effusion compared to the peripheral blood and bone marrow. The change in cell surface phenotype of the lymphocyte population between the diagnostic biopsy and the first passage for PDX established from peripheral blood and bone marrow, is likely due to outgrowth of tumour cells in the mouse with loss of infiltrating immune and other cells. A number of further lines of evidence suggest that changes did not occur to the tumour populations between the initial biopsy and P1: All tumours were almost 100% MYC translocation-positive after P1, matching reports of the original biopsy samples and minor cell populations that were lost from the biopsy sample were shown to be CD20- and hence, most likely healthy immune cells that fell into the same forward and side scatter gate as the BL cells. Insufficient biopsy material meant detailed genomic analysis was not possible for these PDX. However, PDX6 generated from the peritoneal fluid of a relapsed patient had sufficient pre-engraftment and P1 material available for WGS. Analysis of potential functional variants in 4 272 genes associated with BL pathophysiology highlighted that no new variants in BL-related genes emerged or were lost in the xenograft. Furthermore, linear regression analysis identified a strong relationship between VAF before and after engraftment, suggesting that the methodology used for the establishment of the PDX models in this study did not introduce strong selection bias. The stability of the genetic characteristics after engraftment in this PDX is encouraging given that Schmitz et al. highlighted that in xenografted leukaemia, changes in copy number alterations emerged in the majority of cases during the first passage in mice.22 Other studies have also shown the persistence of tumour characteristics upon in vivo passage including a study of MCL PDX which did not observe any genetic alterations in 1 212 cancer-associated genes after two passages.21 Furthermore in a study of adult DLBCL PDXs, a comparison of the mutant allele fraction in primary specimens and the associated PDXs indicated that these models retained the complex genetic signature of primary samples.17 Analysis of the MYC translocation between subsequent passages from P1 onwards in our PDXs showed maintenance of the translocation in all cells at P5. Furthermore, the coefficient of determination for gene expression levels between P1 and P5 was greater than 0.94 for all five PDXs. At the cellular level, the histology of each tumour was maintained over five passages and, significantly, the heterogeneous surface

S. Forde et al.

© 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd
protein expression profile was also highly conserved, highlighting the potential importance of a tightly controlled population equilibrium within the tumours. Following initial engraftment these PDX models consistently produce large tumours within 4–6 weeks and provide an excellent resource to investigate the functional significance of tumour heterogeneity. The response of each PDX to doxorubicin, methotrexate and vincristine, components of the LMB chemotherapeutic backbone for paediatric BL patients, is also encouraging and highlights that they can be used to model therapy response and perhaps to elucidate causes of resistance. Of note, differential sensitivity to chemotherapy was observed among PDXs in this study, highlighting the importance of intertumour heterogeneity in evaluating treatment response and the need for personalised medicine approaches.

In summary, we describe in the largest cohort of BL PDX, based on phenotypical and in-depth molecular characterisation, the persistence of BL characteristics upon serial passaging in mice. These PDX models provide a valuable resource to investigate the functional and clinical significance of the heterogenous populations in BL. These models may be used to elucidate mechanisms of resistance and relapse so we can ultimately improve the dismal prognosis for this patient population.

Acknowledgements

We are grateful to Dave, Nic, Brenda and Matt for their support, courage and determination to put an end to childhood cancer in memory of Alex. SF, JDM, GAAB and SDT are supported with funding from the Alex Hulme Foundation. We thank the Cambridge NIHR BRC Cell Phenotyping Hub, Addenbrooke’s Hospital, Cambridge; Central Biomedical Services (CBS), Addenbrooke’s Hospital, Cambridge; Haematopathology and Oncology Diagnostic Service (HODS) Lab, Addenbrooke’s Hospital, Cambridge; and the Histology Lab, Department of Pathology, University of Cambridge. We are also extremely grateful to all the children and their parents who donated their tumour tissues for this study.

Author contributions

Conceptualization: SF, GAAB, SDT; methodology: SF, JDM and SDT; investigation: SF, JDM, OG, LJ, TIMM; writing — original draft: SF and SDT; writing — review and editing: SF, GAAB, JDM, NP, LK, SDT; writing — final approval: all; funding acquisition: SDT; resources: NB, SB, SDT, AO’M, OS; supervision: SDT, GAAB.

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Fig S1. Bland–Altman plot with marginal histograms.

Fig S2. Bland–Altman plots for patient-derived xenografts (PDXs) 1–5.

References


